Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks.

Authors:
Deborah Moskowitz

Altern Med Rev 2006 Sep;11(3):208-23

Numerous forms of estrogens and progestins are utilized for the treatment of menopausal complaints and associated conditions that occur temporally. Although known to be different with respect to molecular structure, receptor affinity, metabolism, and other physiological traits, most have been treated as if they were clinically identical. The majority of these hormone preparations, commonly referred to as hormone replacement therapy (HRT), should perhaps be more aptly referred to as hormone substitution therapy, as most of the therapies utilized do not exactly match those produced in the body. Research indicates these synthetic hormones vary clinically in safety and efficacy. As such, women and their physicians have, in increasing numbers, been opting for the use of bioidentical hormones; i.e., those that match the structure and function of hormones produced in the body. With greater utilization and research surrounding bioidentical hormones, the differences can now begin to be fully assessed and appreciated. This article reviews the disparities between synthetic and bioidentical estrogens and progestins/progesterone with respect to safety and efficacy; special attention is devoted to clinical outcomes in the breast, endometrium, bone, cardiovascular system, and brain. The studies reviewed suggest bioidentical progesterone does not have a negative effect on blood lipids or vasculature as do many synthetic progestins, and may carry less risk with respect to breast cancer incidence. Studies of both bioidentical estrogens and progesterone suggest a reduced risk of blood clots compared to non-bioidentical preparations. Bioidentical hormone preparations have demonstrated effectiveness in addressing menopausal symptoms. The author advocates for continued research on bioidentical hormones and concludes there is currently sufficient evidence to support their preferred use over that of their synthetic cousins.

Download full-text PDF

Source
September 2006

Publication Analysis

Top Keywords

bioidentical hormones
16
safety efficacy
12
hormone preparations
8
bioidentical estrogens
8
bioidentical
8
produced body
8
referred hormone
8
hormones
6
numbers opting
4
opting bioidentical
4
hormones match
4
match structure
4
clots compared
4
structure function
4
function hormones
4
body greater
4
hormones produced
4
comprehensive review
4
compared non-bioidentical
4
greater utilization
4

Keyword Occurance

Similar Publications

Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.

Authors:
Yi Liu Ying Yuan A J Day Wen Zhang Princy John Danielle J Ng Daniel Banov

Menopause 2022 Feb 14;29(4):465-482. Epub 2022 Feb 14.

Professional Compounding Centers of America (PCCA), Houston, TX.

Importance: More information is needed about the efficacy and safety of compounded bioidentical hormone therapy (cBHT) in the published literature. A thorough synthesis of existing data is not currently available.

Objective: To provide a systematic review and meta-analysis of the existing evidence related to the safety and efficacy of commonly prescribed cBHT preparations in perimenopausal and postmenopausal women. Read More

View Article and Full-Text PDF
February 2022
Similar Publications

Fact or Fiction? The Role of Regulated Body-Identical Hormone Therapy for Menopausal Women.

Authors:
Laura Donnelly Lynda G Balneaves

Nurs Womens Health 2022 Apr 18;26(2):143-151. Epub 2022 Feb 18.

Many menopausal women use hormone therapy, including regulated body-identical hormone therapy (rBHT), to relieve vasomotor symptoms and prevent cardiovascular disease. Despite growing interest in rBHT, there is uncertainty regarding potential benefits and risks. With this narrative review, we aimed to synthesize the literature regarding the efficacy of these therapies for managing vasomotor symptoms and preventing cardiovascular disease. Read More

View Article and Full-Text PDF
April 2022
Similar Publications

Compounded bioidentical hormone products, a path forward.

Authors:
Robert B MacArthur Donald Mattison Ruth M Parker

J Am Pharm Assoc (2003) 2022 Jan-Feb;62(1):42-48. Epub 2021 Aug 9.

Objective: To describe the widespread use of compounded bioidentical hormone therapies (cBHT). To define the term clinical utility and present why there is insufficient evidence to support the overall clinical utility of cBHT products. To recommend actions that pharmacists and regulators can take to promote safer cBHT use. Read More

View Article and Full-Text PDF
January 2022
Similar Publications

Compounded Bioidentical Hormones: Myths and Realities.

Authors:
Nanette Santoro Jill Liss

Clin Obstet Gynecol 2021 12;64(4):793-802

Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.

The spectacular success of compounded bioidentical hormone therapy is a product of the unanticipated negative-to-neutral findings of the Women's Health Initiative hormone trial and the peculiarities of their regulatory status. By not having to provide scientific evidence of safety and efficacy, a requirement for all Food and Drug Administration (FDA)-approved hormone therapy products, the industry's relatively unfettered marketing now accounts for about one third of menopausal hormone therapy prescriptions. Clinicians are often caught in the middle between patient beliefs and a desire to practice evidence-based medicine. Read More

View Article and Full-Text PDF
December 2021
Similar Publications

Environmental obesogens (bisphenols, phthalates and parabens) and their impacts on adipogenic transcription factors in the absence of dexamethasone in 3T3-L1 cells.

Authors:
Sun-Il Choi Hee-Yeon Kwon Xionggao Han Xiao Men Ye-Eun Choi Gill-Woong Jang Keun-Tae Park Jongkwon Han Ok-Hwan Lee

J Steroid Biochem Mol Biol 2021 11 1;214:105994. Epub 2021 Sep 1.

Department of Food Biotechnology and Environmental Science, Kangwon National University, Chuncheon, 24341, Republic of Korea. Electronic address:

Endocrine-disrupting chemicals (EDCs) are exogenous compounds that are capable of blocking or mimicking the action of bioidentical hormones. Obesogenic EDCs, commonly called obesogens, play an important role in adipogenesis. This study was carried out to determine the effects of select obesogens and their alternatives on adipogenesis in 3T3-L1 cells under dexamethasone (DEX)-free conditions. Read More

View Article and Full-Text PDF
November 2021
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap